Business

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Triapine

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Triapine.

articleTron Group Inc.November 2, 20225/company/tron-group-inc/news/nanopharmaceutics-inc-announces-the-end-of-patient-recruitment-for-the-national-cancer-institute-nci-sponsored-phase-3-clinical-study-in-advanced-stage-cervical-and-vaginal-cancers-with-triapine
Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Triapine

About this update from Tron Group Inc.

[{"type":"text","content":"","length":30,"tagName":"div"}]

More updates from Tron Group Inc.